<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Fungal Skin Infections MeG-CLS-057</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h2 id="fungal-skin-infections">Fungal skin infections</h2>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Common fungal skin infections in our environment include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Tinea pedis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tinea cruris</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tinea corporis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Tinea capitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cutaneous candidiasis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pityriasis versicolor</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Seborrhoeic dermatitis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nail infections</p>
</div></li>
</ul>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Gate clinic</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes</h2>
<p>This guideline outlines the management of fungal skin infections in our setting. In most cases topicals can be used in order to reduce the side effects of systemic treatment. Patients must be encouraged to continue treatment until the lesions have disappeared and then for a further week to reduce the incidence of treatment failure.</p>
<h2 id="limitations">Limitations</h2>
<p>Terbinafine is not provided at the clinic and may be unaffordable for most patients.</p>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Most fungal skin infections present with an itchy rash.</p>
<p><strong><span class="underline">Tinea pedis</span>:</strong> Itching and/or burning sensation in the feet. It may present as:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Interdigital: toe-web infection, usually occurs between two smallest toes with redness, blisters or softening and breaking down of the skin</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Moccasin: involves the entire sole of the foot and extend to the sides of the foot with peeling, cracking and scaling of the feet</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vesicular: fluid-filled blisters on the underside of the foot, the toes, the heel or on top of the foot</p>
</div></li>
</ul>
<p><strong><span class="underline">Tinea cruris</span>:</strong> Affects genitals, inner thighs and buttocks. It appears as a red, scaly, itchy rash that is often ring-shaped. It is mildly contagious</p>
<p><strong><span class="underline">Tinea corporis</span>:</strong> Occures anywhere on the body. Each lesion is circular, red, scaly flat lesion. The outer part of the rash is raised while the skin in the middle appears normal. Lesions may coalesce. It is contagious.</p>
<p><strong><span class="underline">Tinea capitis</span>:</strong> Affects the scalp and is most common in children. It is contagious and facilitated by overcrowding and poor hygiene. Features include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Itchy patches on the scalp, scaly, red areas with bald spots</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Broken off hair</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Brittle hair</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Painful scalp</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Crusty swellings which may become bacterially infected (kerion)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Swollen cervical lymph nodes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Low grade fever</p>
</div></li>
</ul>
<p><strong><span class="underline">Cutaneous candidiasis</span>:</strong> Affects nearly any skin surface of the body but most common in warm, moist areas in contact such as the armpits, breast folds and groin. They are common among obese people, diabetics and people on antibiotics. In children, it causes a diaper rash. It presents as itchy or burning red patches that may ooze clear fluid with some surrounding pimple-like bumps. Other presentations include oral/vaginal thrush and nail infection. It is not contagious</p>
<p><strong><span class="underline">Pityriasis (tinea) versicolor</span></strong>: Common among teenagers and young adults. It presents as multiple hypopigmented (light) or hyperpigmented (dark) scaly, dry patches usually over the face, neck, upper arms and trunk. The lesions may be itchy. It is not contagious.</p>
<p><strong><span class="underline">Seborrhoeic dermatitis</span></strong>: Presents on the scalp as dandruff. It also involves the face, neck, trunk and any other hair-bearing area presenting as scaly hypopigmented or red patches. It is not contagious.</p>
<p><strong><span class="underline"><br />
</span></strong></p>
<p><strong><span class="underline">Nail Infections (onychomycosis):</span></strong> May present as thickened and discolored nails. Nails may become, black, yellow or green. The nail may be brittle and may separate from the nail bed. The underlying skin may become inflamed and infected.</p>
<p>If a cutaneous dermatophyte infection is misdiagnosed and initially treated with a topical corticosteroid, the appearance of the infection may be altered, making diagnosis more difficult (i.e., tinea incognito). Patients can develop diminished erythema and scale, loss of a well-defined border, exacerbation of disease, or a deep-seated folliculitis (Majocchi&#39;s granuloma).</p>
<p>The simultaneous presence of more than one type of dermatophyte infection is common (e.g. tinea pedis and tinea cruris or tinea pedis and tinea unguium). Performance of a full skin examination including the skin, hair, and nails aids in the detection of additional sites of infection. Occasionally, patients develop a dermatophytid reaction, a secondary dermatitic reaction at a distant site that may reflect an immunologic reaction to the infection.</p>
<h2 id="management-in-gate-clinic">Management in Gate clinic</h2>
<p>Most fungal skin infections can be treated with topical antifungals. Clotrimazole or miconazole cream can be applied thinly twice daily over localized lesions.</p>
<p>Seborrhoeic dermatitis and pityriasis versicolor can be treated with either ketoconazole shampoo or selenium sulfide shampoo applied to lesions twice weekly. Skin lesions in seborrhoeic dermatitis can also be treated with 1% hydrocortisone cream twice each day until healing occurs.</p>
<p>Tinea capitis can be treated with Whitfield’s ointment applied twice daily. Add cloxacillin 20-25 mg/kg (max 500 mg) QDS for 5 days if kerion is present.</p>
<p><strong>DO NOT</strong> prescribe griseofulvin – as it is teratogenic even up to six months after conception. This is true for both men and women.</p>
<p>Review patients after 4 weeks of treatment to asses improvement. If rash shows some improvement, ask patient to continue treat treatment until one week after lesions have cleared.</p>
<p>Refer patients to the doctor if:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Immunosuppressed (HIV, Diabetes mellitus)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Widespread rash</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Unfamiliar rash / Rash does not appear typical</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>No improvement after 4 weeks of treatment (except nail infections and pityriasis versicolor)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nail infections</p>
</div></li>
</ul>
<h2 id="management-in-opd">Management in OPD</h2>
<p>For patients with widespread rash, atypical rash or minimal improvement on topical therapy, consider alternative diagnosis or background immunosuppression.</p>
<p>HIV testing, VDRL, Fasting blood glucose may assist in diagnosis of unusual rash.</p>
<p>Patients with fungal skin infections and immunosuppression may require systemic(oral) therapy. Options include fluconazole (continuous or pulse therapy), itraconazole or terbinafine. Drug interactions, contra-indications and adverse effects must be considered in drug choice.</p>
<p>Nail Infections: account for less than half of all nail lesions. Treatment of onychomycosis is not mandatory in all patients. Weigh the risk of treatment against potential benefit for each individual patient.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Oral – terbinafine (76% effective), itraconazole (60% effective), or fluconazole (48 % effective). Oral ketoconazole is not usually recommended due to side effects and the need for a long course of treatment. However, it is often the only effective and affordable option in our setting. DO NOT prescribe griseofulvin (see note above).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Others – chemical keratolytic agents (e.g. urea cream), surgical debridement of the affected nails.</p>
</div></li>
</ul>
<p><strong>References</strong></p>
<p>Gupta AK1, Drummond-Main C, Paquet M. Evidence-based optimal fluconazole dosing regimen for onychomycosis treatment. <a href="https://www.ncbi.nlm.nih.gov/pubmed/22694221">J Dermatolog Treat.</a> 2013 Feb;24(1):75-80. doi: 10.3109/09546634.2012.703308</p>
<p>Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, Godse K, Patel K, Rengasamy M, Rudramurthy S, Dogra S. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC dermatology. 2018 Dec;18(1):6.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Danlami Garba</th>
<th>Date: 28 August 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Fatai Akemokwe</td>
<td>Date: 12 September 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 January 2021</td>
</tr>
<tr class="even">
<td>1.1</td>
<td>Executive summary added</td>
<td>31 January 2021</td>
</tr>
<tr class="odd">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
